Giovanna Roncador

List of Publications by Year
in descending order

104 papers	7,492 citations	76326 40 h-index	53230 85 g-index
105 all docs	105 docs citations	105 times ranked	9556 citing authors

#	Article	IF	Citations
1	Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 234-244.	6.7	593
2	Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. European Journal of Immunology, 2005, 35, 1681-1691.	2.9	528
3	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 2011, 43, 663-667.	21.4	478
4	High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 2006, 108, 2957-2964.	1.4	448
5	Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells. Clinical Cancer Research, 2005, 11, 1467-1473.	7.0	401
6	<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
7	High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma. Journal of Clinical Oncology, 2009, 27, 1470-1476.	1.6	273
8	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. Journal of Pathology, 1997, 183, 116-123.	4.5	244
9	Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. American Journal of Surgical Pathology, 2009, 33, 81-90.	3.7	226
10	Peripheral T-cell Lymphomas With a Follicular Growth Pattern are Derived From Follicular Helper T Cells (TFH) and may Show Overlapping Features With Angioimmunoblastic T-cell Lymphomas. American Journal of Surgical Pathology, 2009, 33, 682-690.	3.7	189
11	Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. European Journal of Immunology, 2000, 30, 3552-3561.	2.9	186
12	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. Journal of Pathology, 1997, 183, 116-123.	4.5	179
13	Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma. Laboratory Investigation, 2001, 81, 419-426.	3.7	158
14	A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1–Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages. Clinical Cancer Research, 2010, 16, 637-650.	7.0	151
15	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica, 2007, 92, 1059-1066.	3.5	142
16	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia, 2005, 19, 2247-2253.	7.2	131
17	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.	5.9	130
18	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica, 2010, 95, 1342-1349.	3.5	128

#	ARTICLE	IF	CITATIONS
19	FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. International Immunology, 2007, 19, 825-835.	4.0	124
20	PD-1, a Follicular T-cell Marker Useful for Recognizing Nodular Lymphocyte-predominant Hodgkin Lymphoma. American Journal of Surgical Pathology, 2008, 32, 1252-1257.	3.7	122
21	Peripheral T-cell Lymphoma With Follicular T-cell Markers. American Journal of Surgical Pathology, 2008, 32, 1787-1799.	3.7	115
22	Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas. Leukemia, 2005, 19, 2254-2263.	7.2	112
23	Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immunity, 2007, 7, 7.	3.2	107
24	Detection of Normal and Chimeric Nucleophosmin in Human Cells. Blood, 1999, 93, 632-642.	1.4	101
25	Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clinical Immunology, 2006, 121, 358-368.	3.2	96
26	Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia, 2009, 23, 1847-1857.	7.2	87
27	Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. British Journal of Haematology, 2000, 109, 584-591.	2.5	86
28	NOTCH pathway inactivation promotes bladder cancer progression. Journal of Clinical Investigation, 2015, 125, 824-830.	8.2	86
29	Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia, 2006, 20, 1123-1129.	7.2	85
30	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood, 2011, 118, 5517-5527.	1.4	83
31	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica, 2006, 91, 467-74.	3.5	70
32	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood, 2008, 111, 351-358.	1.4	69
33	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Modern Pathology, 2009, 22, 753-761.	5.5	65
34	Bone Marrow Findings Further Support the Hypothesis that Essential Mixed Cryoglobulinemia Type II is Characterized by a Monoclonal B-Cell Proliferation. Leukemia and Lymphoma, 1995, 20, 119-124.	1.3	55
35	Cancer Abolishes the Tissue Type-Specific Differences in the Phenotype of Energetic Metabolism. Translational Oncology, 2009, 2, 138-145.	3.7	53
36	SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood, 2013, 121, 643-647.	1.4	47

#	Article	IF	Citations
37	The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells. Leukemia, 2006, 20, 1439-1441.	7.2	46
38	The European antibody network's practical guide to finding and validating suitable antibodies for research. MAbs, 2016, 8, 27-36.	5.2	46
39	Lineage-restricted function of the pluripotency factor NANOG in stratified epithelia. Nature Communications, 2014, 5, 4226.	12.8	45
40	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. International Journal of Cancer, 2006, 118, 3161-3166.	5.1	44
41	FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Annals of the Rheumatic Diseases, 2009, 68, 1908-1915.	0.9	41
42	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (<scp>DLBCL</scp>) reveals gain at 1q31 and <scp>RGS</scp>1 encoding protein; high <scp>RGS</scp>1 immunohistochemical expression associates with poor overall survival in <scp>DLBCL</scp> not otherwise specified (<scp>NOS</scp>). Histopathology, 2017, 70, 595-621.	2.9	41
43	Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Human Pathology, 2010, 41, 1726-1734.	2.0	40
44	Transmembrane adaptor molecules: a new category of lymphoid-cell markers. Blood, 2006, 107, 213-221.	1.4	39
45	High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation. Journal of Clinical and Experimental Hematopathology: JCEH, 2019, 59, 1-16.	0.8	36
46	Aberrant expression of the neuronal transcription factor *FOXP2* in neoplastic plasma cells. British Journal of Haematology, 2010, 149, 221-230.	2.5	34
47	Proliferation centers in chronic lymphocytic leukemia: the niche where NF-κB activation takes place. Leukemia, 2010, 24, 872-876.	7.2	34
48	Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. Human Pathology, 2014, 45, 1730-1736.	2.0	34
49	CD4/CD8 Double Negative Mycosis Fungoides With PD-1 (CD279) Expression—A Disease of Follicular Helper T-Cells?. American Journal of Dermatopathology, 2012, 34, 757-761.	0.6	32
50	Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. Oncotarget, 2018, 9, 16124-16133.	1.8	30
51	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0125203.	2.5	30
52	Simultaneous detection of the immunophenotypic markers and genetic aberrations on routinely processed paraffin sections of lymphoma samples by means of the FICTION technique. Leukemia, 2004, 18, 348-353.	7.2	28
53	PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia, 2006, 20, 2172-2174.	7.2	27
54	Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica, 2009, 94, 419-422.	3.5	27

#	Article	IF	Citations
55	p38Î± limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene, 2012, 31, 4447-4459.	5.9	26
56	Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients. American Journal of Surgical Pathology, 2018, 42, 936-950.	3.7	26
57	The Antibody Societyâ€™s antibody validation webinar series. MAbs, 2020, 12, 1794421.	5.2	26
58	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25
59	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel. Cancers, 2021, 13, 6384.	3.7	24
60	High <i>PTX3</i> expression is associated with a poor prognosis in diffuse large Bâ€cell lymphoma. Cancer Science, 2022, 113, 334-348.	3.9	23
61	Expression of programmed death-1 (CD279) in primary cutaneous B-cell lymphomas with correlation to lymphoma entities and biological behaviour. British Journal of Dermatology, 2013, 169, 1212-1218.	1.5	19
62	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. PLoS ONE, 2014, 9, e112148.	2.5	18
63	Bclâ€2 and BLIMPâ€1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful. Histopathology, 2012, 60, 785-792.	2.9	17
64	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. Oncotarget, 2016, 7, 52940-52956.	1.8	16
65	Immunohistochemical screening for oncogenic tyrosine kinase activation. , 1999, 187, 588-593.		14
66	High Expression of Caspase-8 Associated with Improved Survival in Diffuse Large B-Cell Lymphoma: Machine Learning and Artificial Neural Networks Analyses. BioMedInformatics, 2021, 1, 18-46.	2.0	14
67	Integrative Statistics, Machine Learning and Artificial Intelligence Neural Network Analysis Correlated CSF1R with the Prognosis of Diffuse Large B-Cell Lymphoma. Hemato, 2021, 2, 182-206.	0.6	13
68	Genetic Immunization: A New Monoclonal Antibody for the Detection of BCL-6 Protein in Paraffin Sections. Journal of Histochemistry and Cytochemistry, 2006, 54, 31-38.	2.5	12
69	Nkx2-3â€"A Slippery Slope From Development Through Inflammation Toward Hematopoietic Malignancies. Biomarker Insights, 2018, 13, 117727191875748.	2.5	12
70	Immunohistochemistry of Bone-Marrow Biopsy. Leukemia and Lymphoma, 1997, 26, 69-75.	1.3	11
71	Elevated receptor for activated C kinase 1 expression is involved in intracellular Ca²⁺ influx and potentially associated with compromised regulatory T cell function in patients with asthma. Clinical and Experimental Allergy, 2014, 44, 1154-1169.	2.9	10
72	Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity. Pathology International, 2019, 69, 260-271.	1.3	10

#	Article	IF	Citations
73	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. PLoS ONE, 2020, 15, e0229743.	2.5	10
74	Impaired Ca^{2+} Regulation of $CD4^+CD25^+$ Regulatory T Cells from Pediatric Asthma. International Archives of Allergy and Immunology, 2011, 156, 148-158.	2.1	9
75	RNASET2 â€" An autoantigen in anaplastic large cell lymphoma identified by protein array analysis. Journal of Proteomics, 2012, 75, 5279-5292.	2.4	9
76	BCL7A protein expression in normal and malignant lymphoid tissues. British Journal of Haematology, 2013, 160, 106-109.	2.5	9
77	Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. Immunology Letters, 2011, 134, 150-156.	2.5	8
78	Follicular Tâ€cell lymphoma: description of a case with characteristic findings suggesting it is a different condition from AITL. Histopathology, 2009, 54, 902-904.	2.9	7
79	Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas. Biomarker Insights, 2014, 9, BMI.S16553.	2.5	7
80	KLHL6 Is Preferentially Expressed in Germinal Centerâ€"Derived B-Cell Lymphomas. American Journal of Clinical Pathology, 2017, 148, 465-476.	0.7	7
81	Participation of Th17 and Treg Cells in Pediatric Bronchial Asthma. Journal of Health Science, 2010, 56, 589-597.	0.9	6
82	Anti-HBV drug entecavir ameliorates DSS-induced colitis through PD-L1 induction. Pharmacological Research, 2022, 179, 105918.	7.1	5
83	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. Human Pathology, 2022, 124, 67-75.	2.0	4
84	Generation of a New Monoclonal Antibody Against MALT1 by Genetic Immunization. Hybridoma, 2007, 26, 86-91.	0.4	3
85	A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome,. Blood, 2011, 118, 3684-3684.	1.4	3
86	pâ€‹scp>MAPK</scp>1 expression associated with poor prognosis in angioimmunoblastic Tâ€cell lymphoma patients. British Journal of Haematology, 2017, 176, 661-664.	2.5	2
87	Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma. Blood, 2008, 112, 2815-2815.	1.4	2
88	TOX Expression in Mycosis Fungoides and Sezary Syndrome. Diagnostics, 2022, 12, 1582.	2.6	2
89	Comparison of Choi and Hans' Algorithms by Immunohistochemistry and Quantitative Reverse Transcriptase-PCR â€" Letter. Clinical Cancer Research, 2010, 16, 3805-3806.	7.0	1
90	Immunohistochemical screening for oncogenic tyrosine kinase activation. Journal of Pathology, 1999, 187, 588-593.	4.5	1

#	Article	IF	Citations
91	Peripheral T-Cell Lymphomas with Follicular Growth Patterns Are Derived from Follicular Helper T Cells (TFH): A Link with Angioimmunoblastic T-Cell Lymphomas?.. Blood, 2007, 110, 3568-3568.	1.4	1
92	CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers, 2022, 14, 2154.	3.7	1
93	In Response. American Journal of Dermatopathology, 2014, 36, 103.	0.6	0
94	Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 482-485.	1.3	0
95	Identification of Candidate Oncogenes in Acute Megakaryoblastic Leukemias with Gain of Chromosome 19.. Blood, 2004, 104, 2023-2023.	1.4	0
96	FOXP3 Expression in B and T Cell Lymphomas.. Blood, 2005, 106, 4503-4503.	1.4	0
97	BCL11AXL Protein: Its Distribution in Normal and Malignant Tissues and Use as a Marker for Plasmacytoid Dendritic Cells.. Blood, 2005, 106, 4392-4392.	1.4	0
98	Human BCL11B Is Expressed in Normal T Cells and Differentially Expressed in T-Cell Malignancies.. Blood, 2005, 106, 4393-4393.	1.4	0
99	PIM as a Rational Target for B-Cell Lymphomas.. Blood, 2009, 114, 3946-3946.	1.4	0
100	Several Immune Cell Subsets Are Associated with Outcome in the Microenvironment of Follicular Lymphoma.. Blood, 2009, 114, 3953-3953.	1.4	0
101	Title is missing!. , 2020, 15, e0229743.		0
102	Title is missing!. , 2020, 15, e0229743.		0
103	Title is missing!. , 2020, 15, e0229743.		0
104	Title is missing!. , 2020, 15, e0229743.		0